Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.

Blonda, Alessandra; Barcina Lacosta, Teresa; Toumi, Mondher; Simoens, Steven

Blonda, Alessandra; Barcina Lacosta, Teresa; Toumi, Mondher; Simoens, Steven.

Afiliación

Blonda A; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Barcina Lacosta T; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Toumi M; Department of Public Health, Aix-Marseille Université, Marseille, France.
Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Front Pharmacol ; 12: 750742, 2021.

Article en En | MEDLINE | ID: mdl-35126102

Palabras clave

budget impact; cost-effectiveness; health technology assessment (HTA); managed entry agreement (MEA); nusinersen (spinraza); reimbursement; spinal muscular atrophy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_technology_assessment / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google